ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesGlobeNewsWire • Wednesday
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorGlobeNewsWire • 09/23/26
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026GlobeNewsWire • 09/09/26
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementGlobeNewsWire • 06/25/26
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformGlobeNewsWire • 06/25/26
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformGlobeNewsWire • 05/11/26
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026GlobeNewsWire • 05/04/26
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsGlobeNewsWire • 04/30/26
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventGlobeNewsWire • 04/08/26
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardGlobeNewsWire • 04/08/26
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026GlobeNewsWire • 03/25/26
ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptSeeking Alpha • 03/18/26
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences ConferenceGlobeNewsWire • 03/03/26
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 OutlookGlobeNewsWire • 01/08/26